Recommended

Sarepta’s DMD drug Elevidys issued FDA label update
Rare disease gene therapy granted European first approval
Johnson & Johnson agrees $3bn oncology acquisition
European Commission grants EU first for J&J’s Simponi biosimilar
Researchers validate approach that supports animal-based pyrogen test replacement
ON DEMAND webinar: automating QC testing for radiopharmaceutical production
Insmed secures EU approval for Brinsupri (brensocatib)
Moderna invests over $140m to onshore mRNA medicine manufacturing in US
news

ABPI finds £377 million spent on UK R&D

4
SHARES

The ABPI has reported findings from its transparency initiative, Disclosure UK, stating that R&D investment grew significantly from 2017 to 2018.

New figures published by the Association of the British Pharmaceutical Industry (ABPI) state that £377.3 million was invested in research and development (R&D) in the UK during 2018. According to the ABPI, this is an increase from the £370.9 million spent in 2017.

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

The data was published by Disclosure UK, an initiative to improve transparency in the pharmaceutical industry for healthcare professionals (HCPs) and organisations (HCOs).

In the report, 57.2 percent of HCPs agreed for their payments received from pharmaceutical companies to be made public.

The findings show that another £130.8 million was spent by pharmaceutical companies on non-R&D collaborations with HCPs and HCOs, with 83.1 percent of this disclosed against a named person or organisation.

Of this figure, £28.9 million was spent on sponsorship agreements with HCOs and third parties and £3.5 million was spent on registration fees.

Mike Thompson, Chief Executive of the ABPI, said the “continued investment from companies is excellent news at a time of economic uncertainty and signals the strength of the sector in the UK. We can’t discover or bring to market new medicines without the expertise of doctors and nurses. It’s vital that companies can collaborate with those people, and that we’re open and transparent about any payments we make to them.”

Share via
Share via